Increasing AQST position size by about 15%.

About a 55-60% discount to $SPRY here. Expect that gap to gradually close, but some consolidation is healthy.

Libervant PDUFA in April, potential licensing/partnership announcement for both Libervant and Anaphylm this year, Anaphylm NDA likely towards end of year, and more info on AQST-108 throughout 2024...

Reiterating that AQST looks like a strong long-term hold.